Feasibility of Early Gabapentin as an Intervention for Neurorecovery

• Status: Recruiting
• Trial end date: 2026-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of the proposed study is to conduct the first ever prospective, dose-exploration trial to test the feasibility of early administration of gabapentin as an intervention for neurorecovery. This research project falls under the Intervention Development stage of research as the primary goal is to assess the feasibility of conducting a well-designed intervention efficacy study in the future.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: MetroHealth Medical Center
• Collaborator: National Institute on Disability, Independent Living, and Rehabilitation Research
• Treatments: Gabapentin

Criteria

Inclusion Criteria:

1. Traumatic SCI;

2. All levels of SCI;

3. All severities of SCI, AIS A-D;

4. Age 18 years and older.

5. Agree to participate and start study drug within 120 hours' post-injury.

6. Adequate cognition and communication to provide informed consent

Exclusion Criteria:

1. Presence of moderate/severe traumatic brain injury (TBI) as defined by Glasgow Coma Score (GCS) < 13 at 120 hours' post-injury.

2. Documented use of gabapentinoids at the time of injury.